143 related articles for article (PubMed ID: 37935707)
21. Fenretinide via NOXA Induction, Enhanced Activity of the BCL-2 Inhibitor Venetoclax in High BCL-2-Expressing Neuroblastoma Preclinical Models.
Nguyen TH; Koneru B; Wei SJ; Chen WH; Makena MR; Urias E; Kang MH; Reynolds CP
Mol Cancer Ther; 2019 Dec; 18(12):2270-2282. PubMed ID: 31484706
[TBL] [Abstract][Full Text] [Related]
22. Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma.
Zinzani PL; Flinn IW; Yuen SLS; Topp MS; Rusconi C; Fleury I; Le Dû K; Arthur C; Pro B; Gritti G; Crump M; Petrich A; Samineni D; Sinha A; Punnoose EA; Szafer-Glusman E; Spielewoy N; Mobasher M; Humphrey K; Kornacker M; Hiddemann W
Blood; 2020 Dec; 136(23):2628-2637. PubMed ID: 32785666
[TBL] [Abstract][Full Text] [Related]
23. Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial.
Hogarty MD; Ziegler DS; Franson A; Chi YY; Tsao-Wei D; Liu K; Vemu R; Gerner EW; Bruckheimer E; Shamirian A; Hasenauer B; Balis FM; Groshen S; Norris MD; Haber M; Park JR; Matthay KK; Marachelian A
Br J Cancer; 2024 Mar; 130(5):788-797. PubMed ID: 38200233
[TBL] [Abstract][Full Text] [Related]
24. Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study.
Rutherford SC; Abramson JS; Bartlett NL; Barta SK; Khan N; Joyce R; Maddocks K; Ali-Shaw T; Senese S; Yuan Y; Westin J; Leonard JP
Lancet Haematol; 2021 Nov; 8(11):e818-e827. PubMed ID: 34634256
[TBL] [Abstract][Full Text] [Related]
25. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study.
Bazinet A; Darbaniyan F; Jabbour E; Montalban-Bravo G; Ohanian M; Chien K; Kadia T; Takahashi K; Masarova L; Short N; Alvarado Y; Yilmaz M; Ravandi F; Andreeff M; Kanagal-Shamanna R; Ganan-Gomez I; Colla S; Qiao W; Huang X; McCue D; Mirabella B; Kantarjian H; Garcia-Manero G
Lancet Haematol; 2022 Oct; 9(10):e756-e765. PubMed ID: 36063832
[TBL] [Abstract][Full Text] [Related]
26. A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma.
Federico SM; McCarville MB; Shulkin BL; Sondel PM; Hank JA; Hutson P; Meagher M; Shafer A; Ng CY; Leung W; Janssen WE; Wu J; Mao S; Brennan RC; Santana VM; Pappo AS; Furman WL
Clin Cancer Res; 2017 Nov; 23(21):6441-6449. PubMed ID: 28939747
[No Abstract] [Full Text] [Related]
27. Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors.
Kushner BH; Kramer K; Meyers PA; Wollner N; Cheung NK
Med Pediatr Oncol; 2000 Nov; 35(5):468-74. PubMed ID: 11070479
[TBL] [Abstract][Full Text] [Related]
28. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.
DiNardo CD; Rausch CR; Benton C; Kadia T; Jain N; Pemmaraju N; Daver N; Covert W; Marx KR; Mace M; Jabbour E; Cortes J; Garcia-Manero G; Ravandi F; Bhalla KN; Kantarjian H; Konopleva M
Am J Hematol; 2018 Mar; 93(3):401-407. PubMed ID: 29218851
[TBL] [Abstract][Full Text] [Related]
29. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.
Moreau P; Chanan-Khan A; Roberts AW; Agarwal AB; Facon T; Kumar S; Touzeau C; Punnoose EA; Cordero J; Munasinghe W; Jia J; Salem AH; Freise KJ; Leverson JD; Enschede SH; Ross JA; Maciag PC; Verdugo M; Harrison SJ
Blood; 2017 Nov; 130(22):2392-2400. PubMed ID: 28847998
[TBL] [Abstract][Full Text] [Related]
30. Prolonged response to oral gefitinib, cyclophosphamide, and topotecan in heavily pretreated relapsed stage 4 neuroblastoma: a case report.
Donfrancesco A; Jenkner A; De Ioris MA; Ilari I; Castellano A; De Laurentis C; Garganese MC; Milano GM; Dominici C
J Pediatr Hematol Oncol; 2007 Nov; 29(11):799-803. PubMed ID: 17984703
[TBL] [Abstract][Full Text] [Related]
31. Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial.
Simon T; Längler A; Harnischmacher U; Frühwald MC; Jorch N; Claviez A; Berthold F; Hero B
J Cancer Res Clin Oncol; 2007 Sep; 133(9):653-61. PubMed ID: 17479288
[TBL] [Abstract][Full Text] [Related]
32. Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine.
Buettner R; Nguyen LXT; Morales C; Chen MH; Wu X; Chen LS; Hoang DH; Hernandez Vargas S; Pullarkat V; Gandhi V; Marcucci G; Rosen ST
J Hematol Oncol; 2021 Apr; 14(1):70. PubMed ID: 33902674
[TBL] [Abstract][Full Text] [Related]
33. Frontline treatment in CLL: the case for time-limited treatment.
Lévy V; Delmer A; Cymbalista F
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):59-67. PubMed ID: 34889444
[TBL] [Abstract][Full Text] [Related]
34. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
[TBL] [Abstract][Full Text] [Related]
35. [Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience].
Yu WJ; Jia JS; Wang J; Tang FF; Gong LZ; Liu XH; Zhu XL; Zhao XS; Huang XJ; Jiang H
Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):134-140. PubMed ID: 35381674
[No Abstract] [Full Text] [Related]
36. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
37. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
Stilgenbauer S; Eichhorst B; Schetelig J; Coutre S; Seymour JF; Munir T; Puvvada SD; Wendtner CM; Roberts AW; Jurczak W; Mulligan SP; Böttcher S; Mobasher M; Zhu M; Desai M; Chyla B; Verdugo M; Enschede SH; Cerri E; Humerickhouse R; Gordon G; Hallek M; Wierda WG
Lancet Oncol; 2016 Jun; 17(6):768-778. PubMed ID: 27178240
[TBL] [Abstract][Full Text] [Related]
38. Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome.
Davids MS; Rogers KA; Tyekucheva S; Wang Z; Pazienza S; Renner SK; Montegaard J; Ihuoma U; Lehmberg TZ; Parry EM; Wu CJ; Jacobson CA; Fisher DC; Thompson PA; Brown JR
Blood; 2022 Feb; 139(5):686-689. PubMed ID: 34788401
[TBL] [Abstract][Full Text] [Related]
39. A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies.
Paik PK; Rudin CM; Brown A; Rizvi NA; Takebe N; Travis W; James L; Ginsberg MS; Juergens R; Markus S; Tyson L; Subzwari S; Kris MG; Krug LM
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1079-85. PubMed ID: 20165849
[TBL] [Abstract][Full Text] [Related]
40. Real-world results of venetoclax combined with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukemia.
Xu X; Liu R; He A; Wang F
Hematology; 2023 Dec; 28(1):2265206. PubMed ID: 37796109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
